![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, August 14, 2013 11:09:33 AM
1. Stage 1 Audit with TUV SUD America was completed on 2/26/13.
2. Stage 2 Audit for ISO 13485 is scheduled 8/16/13; once completed and CE certification obtained, MammoView devices will be able to be sold in Canada and EU.
3. Solos Endoscopy has retained Emergo Group as authorized representative in Europe.
4. Core business is development and marketing of medical technology, applications, medical devices and procedural techniques.
5. Assets decreased, but so did liabilities.
6. Positive Net Book Value.
7. Increase of sales from same period last year.
8. Increase in revenues.
9. Expenses decreased as did Net Loss.
10. Stock was issued to CEO, not cash, for salary.
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM